An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158306 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Johanna Pohl und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, Ulm University Medical Center, 89081 Ulm, Germany. Hauptthemen laut MEDLINE: Receptors, CXCR4, Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, German Research Foundation (DFG), Bausteinprogramm.
Abstract (Originalsprache)
Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by reciprocal chromosomal translocation between chromosome 9 and 22, leading to the expression of constitutively active oncogenic BCR–ABL1 fusion protein. CXC chemokine receptor 4 (CXCR4) is essential for the survival of BCR–ABL1-transformed mouse pre-B cells, as the deletion of CXCR4 induces death in these cells. To investigate whether CXCR4 inhibition also effectively blocks BCR–ABL1-transformed cell growth in vitro, in this study, we explored an array of peptide-based inhibitors of CXCR4. The inhibitors were optimized derivatives of EPI-X4, an endogenous peptide antagonist of CXCR4. We observed that among all the candidates, EPI-X4 JM#170 (referred to as JM#170) effectively induced cell death in BCR–ABL1-transformed mouse B cells but had little effect on untransformed wild-type B cells. Importantly, AMD3100, a small molecule inhibitor of CXCR4, did not show this effect. Treatment with JM#170 induced transient JNK phosphorylation in BCR–ABL1-transformed cells, which in turn activated the intrinsic apoptotic pathway by inducing cJun, Bim, and Bax gene expressions. Combinatorial treatment of JM#170 with ABL1 kinase inhibitor Imatinib exerted a stronger killing effect on BCR–ABL1-transformed cells even at a lower dose of Imatinib. Surprisingly, JM#170 actively killed Sup-B15 cells, a BCR–ABL1+ human ALL cell line, but had no effect on the BCR–ABL1− 697 cell line. This suggests that the inhibitory effect of JM#170 is specific for BCR–ABL1+ ALL. Taken together, JM#170 emerges as a potent novel drug against Ph+ ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunology, Ulm University Medical Center, 89081 Ulm, Germany.
- Core Facility Functional Peptidomics, Ulm University Medical Center, 89081 Ulm, Germany.
- Core Unit Mass Spectrometry and Proteomics, Ulm University Medical Center, 89081 Ulm, Germany.
- Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.
ORCID-Profile: Omar El Ayoubi, Armando Rodríguez-Alfonso, Ludger Ständker, Mirja Harms, Jan Münch, Hassan Jumaa, Moumita Datta
Förderung
- Deutsche Forschungsgemeinschaft
- German Research Foundation (DFG)
- Bausteinprogramm
- Baden-Württemberg Foundation
Zitieren
APA
Pohl, J., Litz, A., El Ayoubi, O., Rodríguez-Alfonso, A., Ständker, L., Harms, M., Münch, J., Jumaa, H., & Datta, M. (2024). An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158306
Vancouver
Pohl J, Litz A, El Ayoubi O, Rodríguez-Alfonso A, Ständker L, Harms M, et al. An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158306
BibTeX
@article{Pohl2024,
author = {Pohl, Johanna and Litz, Angela and El Ayoubi, Omar and Rodríguez-Alfonso, Armando and Ständker, Ludger and Harms, Mirja and Münch, Jan and Jumaa, Hassan and Datta, Moumita},
title = {An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158306}
}
EUVIMED